Intra-Cellular Therapies Inc. [ITCI] SVP of Finance CFO makes an insider sale of 65,164 shares worth $2.97 million.

0
8

Intra-Cellular Therapies Inc.’s recently made public that its SVP of Finance CFO Hineline Lawrence J. unloaded Company’s shares for reported $2.97 million on Sep 21. In the deal valued at $45.63 per share,65,164 shares were sold. As a result of this transaction, Hineline Lawrence J. now holds 0 shares worth roughly $ 0.0.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Then, VAN NOSTRAND ROBERT L sold 30,000 shares, generating $1,713,975 in total proceeds. Upon selling the shares at $57.13, the Director now owns 9,043 shares.

Before that, MARCUS JOEL S sold 10,000 shares. Intra-Cellular Therapies Inc. shares valued at $592,200 were divested by the Director at a price of $59.22 per share. As a result of the transaction, MARCUS JOEL S now holds 44,233 shares, worth roughly $2.27 million.

Goldman downgraded its Intra-Cellular Therapies Inc. [ITCI] rating to a Neutral from a a Buy in a research note published on Friday, August 22, 2022; the price target was decreased to $49 from $64. PT values the company’s stock at a premium of -4.53 to its Friday closing price. A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. UBS began covering ITCI with “Buy” recommendation on June 14, 2022. Piper Sandler started covering the stock on April 22, 2022. It rated ITCI as “a Neutral”.

Price Performance Review of ITCI

On Friday, Intra-Cellular Therapies Inc. [NASDAQ:ITCI] saw its stock fall -1.27% to $51.22. On the same session, the stock had its day’s lowest price of $49.70, but rose to a high of $53.00. Over the last five days, the stock has gained 10.48%. Intra-Cellular Therapies Inc. shares have fallen nearly -2.14% since the year began. Nevertheless, the stocks have risen 11.28% over the past one year. While a 52-week high of $66.00 was reached on 04/07/22, a 52-week low of $34.43 was recorded on 01/21/22. SMA at 50 days reached $47.82, while 200 days put it at $53.51. A total of 1.01 million shares were traded, compared to the trading of 1.32 million shares in the previous session.

Levels Of Support And Resistance For ITCI Stock

The 24-hour chart illustrates a support level at 49.61, which if violated will result in even more drops to 48.01. On the upside, there is a resistance level at 52.91. A further resistance level may holdings at 54.61. The Relative Strength Index (RSI) on the 14-day chart is 61.05, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.98, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 19.47%. Stochastics %K at 69.48% indicates the stock is a holding.

How much short interest is there in Intra-Cellular Therapies Inc.?

A steep rise in short interest was recorded in Intra-Cellular Therapies Inc. stocks on Jul 14, 2022, growing by 0.12 million shares to a total of 3.71 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 3.59 million shares. There was a rise of 3.23%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 4.53% of the overall stock float, the days-to-cover ratio (short ratio) rose to 4.79.

Intra-Cellular Therapies Inc. [ITCI] – Who Are The Largest Shareholders?

In filings from Fidelity Management & Research Co, it is revealed that the company now owns 10,317,288 shares, or roughly 10.93% of the outstanding ITCI shares. In other words, the investor’s shares have fallen by -568,753 from its previous 13-F filing of 10886041.0. Additionally, The Vanguard Group, Inc. increased 3.68% of its stake after which the total value it holdings stand at $365,246,029, while BlackRock Fund Advisors added 10.78% of its stake to hold $279.82 million in the firm. Over the last quarter, Wasatch Advisors, Inc. sold -2,086,803 shares of Intra-Cellular Therapies Inc., while Wellington Management Co. LLP sold 402,198 shares. At present, Bellevue Asset Management AG is holding 3,349,379 shares valued at $155.85 million. AllianceBernstein LP owned 2,112,587 shares of the company at the time of its most recent 13F filing, worth $98.3 million.

According to FactSet, Intra-Cellular Therapies Inc.’s share price will average $68.69 in the next year, based on opinions of analysts polled by the firm. This is up nearly 33.0 percent from its previous closing price of $51.88. Analysts expect Intra-Cellular Therapies Inc. stock to reach the higher price of $93.00, while the lowest price estimate is $50.00. However, 13 analysts have rated ITCI stock as a Buy in their predictions for 2022. The most recent change occurred on February 16, 2022 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $64 price target.

LEAVE A REPLY

Please enter your comment!
Please enter your name here